Pioglitazone
- Generic Name
- Pioglitazone
- Brand Names
- Actoplus Met, Actos, Duetact, Incresync, Oseni, Tandemact, Pioglitazone Accord, Pioglitazone Actavis
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20N2O3S
- CAS Number
- 111025-46-8
- Unique Ingredient Identifier
- X4OV71U42S
- Background
Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus. It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert in vivo with little consequence. The thiazolidinedione class of medicatio...
- Indication
Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also available in combination with metformin, glimepiride, or alogliptin for the same indication.
- Associated Conditions
- Diabetes, Diabetic Neuropathies, Type 2 Diabetes Mellitus
- Associated Therapies
- -
Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- EMS
- Target Recruit Count
- 480
- Registration Number
- NCT05028140
Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Getz Pharma
- Target Recruit Count
- 123
- Registration Number
- NCT04976283
- Locations
- 🇵🇰
Aga Khan University Hospital, Karachi, Sindh, Pakistan
Pioglitazone as an Adjunct to Cognitive-Behavioral Therapy for Cocaine Relapse Prevention
- Conditions
- Interventions
- First Posted Date
- 2021-04-13
- Last Posted Date
- 2024-12-06
- Target Recruit Count
- 60
- Registration Number
- NCT04843046
- Locations
- 🇺🇸
UTHealth Center for Neurobehavioral Research on Addiction, Houston, Texas, United States
Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- University of Leeds
- Target Recruit Count
- 57
- Registration Number
- NCT04657939
- Locations
- 🇬🇧
Leeds Teaching Hospitals Trust, Leeds, West Yorkshire, United Kingdom
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
- Conditions
- Interventions
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 166
- Registration Number
- NCT04501406
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study
- First Posted Date
- 2020-07-16
- Last Posted Date
- 2020-12-04
- Lead Sponsor
- Samaritan Health Services
- Target Recruit Count
- 10
- Registration Number
- NCT04473274
- Locations
- 🇺🇸
Good Samaritan Hospital Corvallis, Corvallis, Oregon, United States
Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases
- Conditions
- Interventions
- First Posted Date
- 2019-04-10
- Last Posted Date
- 2021-04-29
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 51
- Registration Number
- NCT03910361
- Locations
- 🇰🇷
Soonchunhyang University Hospital, Cheonan, Korea, Republic of
🇰🇷Hanyang University Guri Hospital, Guri-si, Korea, Republic of
🇰🇷Samsung Medical Center, Changwon, Korea, Republic of
Insulin Regulation of Lipolysis and Lipolysis Proteins
- Conditions
- Interventions
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 64
- Registration Number
- NCT03866408
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy
- Conditions
- Interventions
- First Posted Date
- 2019-03-06
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Pujol, Aurora, M.D.
- Target Recruit Count
- 18
- Registration Number
- NCT03864523
- Locations
- 🇪🇸
Donostia University Hospital, Donostia, Spain
🇪🇸Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain
Effects of Pioglitazone on Stress Reactivity and Alcohol Craving (Pilot)
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2020-10-26
- Target Recruit Count
- 4
- Registration Number
- NCT03860753
- Locations
- 🇺🇸
The University of Texas Health Science at Houston, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.